AzurRx BioPharma, Inc. (AZRX) financial statements (2020 and earlier)

Company profile

Business Address 760 PARKSIDE AVENUE
BROOKLYN, NY 11226
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2112
Cash and cash equivalents2112
Receivables2311
Prepaid expense0100
Total current assets:4523
Noncurrent Assets
Operating lease, right-of-use asset0
Property, plant and equipment0000
Intangible assets, net (including goodwill)5222
Goodwill2222
Intangible assets, net (excluding goodwill)4   
Other undisclosed noncurrent assets0112
Total noncurrent assets:6344
TOTAL ASSETS:9757
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:3211
Accounts payable3211
Accrued liabilities1000
Employee-related liabilities0000
Interest and dividends payable0 00
Other undisclosed accounts payable and accrued liabilities(1)(1)(0)(0)
Debt0000
Due to related parties1111
Other liabilities1   
Other undisclosed current liabilities2 00
Total current liabilities:6322
Noncurrent Liabilities
Liabilities, other than long-term debt0   
Other liabilities0   
Other undisclosed noncurrent liabilities  11
Total noncurrent liabilities:0 11
Total liabilities:6344
Stockholders' equity
Stockholders' equity attributable to parent3423
Common stock0000
Additional paid in capital66533828
Accumulated other comprehensive loss(1)(1)(1)(1)
Accumulated deficit(61)(48)(34)(23)
Stockholders' equity note, subscriptions receivable  (1) 
Total stockholders' equity:3423
TOTAL LIABILITIES AND EQUITY:9757

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
Operating expenses(18)(13)(10)(7)
Other undisclosed operating income (loss)0(0)(0)0
Operating loss:(18)(13)(10)(6)
Interest and debt expense(0)(0)(1)(6)
Loss from continuing operations before equity method investments, income taxes:(18)(14)(11)(12)
Other undisclosed loss from continuing operations before income taxes   (2)
Net loss available to common stockholders, diluted:(18)(14)(11)(15)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
Net loss:(18)(14)(11)(15)
Comprehensive loss:(18)(14)(11)(15)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)(0)1(0)
Comprehensive loss, net of tax, attributable to parent:(18)(14)(11)(15)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: